Reports in the New York Times and Eyewire News have indicated that Novartis has launched an internal review of information that raises serious safety concerns… Read More »Reports have identified concerns for medical complications from Novartis’ brolucizumab (Beovu) product for wet AMD.
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a gene therapy company in Florida, has reported encouraging interim six-month data from dose-escalation cohorts of a Phase 1/2… Read More »Applied Genetic Technologies Corporation (Nasdaq: AGTC) reports interim Phase 1/2 achromatopsia study data
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) recently announced the completion of the acquisition of the gene therapy company,… Read More »Roche acquisition of Spark Therapeutics continues to build gene therapy market
NanoDimension, a venture capital company in Lausanne, and Novartis Venture Fund in Basel, have launched a new ophthalmology company, Arctos Ltd., to develop viral vector… Read More »NanoDimension and Novartis Venture Fund invest CHF 8 million for optogenetic retinal gene therapies
Limelight Bio, a new biopharmaceutical company, located closely to the University of Pennsylvania’s Centre for Advanced Retinal and Ocular Therapies (CAROT), has raised $75M equity.… Read More »Limelight Bio has reported a $75M investment focused on a lead gene-therapy ocular program
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced that… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN) aims to dose first LCA10 patients for CRISPR gene therapy in Q1 2020
REGENXBIO Inc. (Nasdaq: RGNX), a clinical stage gene therapy company, has halted a FDA clinical trial on an AAV anti-VEGF product (RGX-314) for wet AMD… Read More »In follow-up to legal dispute, two commercial trials are halted by FDA on anti-VEGF trials in AMD and diabetic retinopathy
Allergan plc (NYSE: AGN) announced a voluntary recall of its XEN 45 glaucoma drainage device after a small number of units in an unreleased lot… Read More »Allergan issues an urgent device recall for the XEN® Glaucoma Treatment System (XEN® 45 Gel Stent)
Novartis AG (NYSE:NVS; SIX:NOVN) has announced that the U.S. Food and Drug Administration (FDA) has approved brolucizumab (“Beovu”) injection (also known as RTH258) for the… Read More »Novartis announces that FDA brolucizumab injection approves to be noninferior to aflibercept in Phase III studies
Gyroscope Therapeutics Ltd., based in Stevenage, UK, has announced the successful completion of a £50.4 million investment to advance clinical development of an investigational gene… Read More »A UK gene therapy company – Gyroscope Therapeutics Ltd – raises £50.4 million funding for retinal disease treatment